The changing face of hepatitis C in the new era of direct-acting antivirals

Antiviral Research

Volumn 97, Issue 1, 2013, Pages 36-40

  Soriano, Vincent ^a   Labarga, Pablo ^a   Fernández Montero, Jose V ^a   Benito, Jose M ^a   Poveda, Eva ^a   Rallon, Norma ^a   Sánchez, Clara ^a   Vispo, Eugenia ^a   Barreiro, Pablo ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 333; ABT 450; ANTIVIRUS AGENT; ASUNAPREVIR; BI 7127; BOCEPREVIR; DANOPREVIR; FALDAPREVIR; GS 9256; IDX 184; MERICITABINE; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; AUTOIMMUNE THYROIDITIS; CRYOGLOBULINEMIA; DRUG TOLERABILITY; HEPATITIS C; HUMAN; IMMIGRANT; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOCIAL EXCLUSION; VIRUS REPLICATION; VIRUS TRANSMISSION; WORKLOAD;

ANTIVIRAL AGENTS; ASYMPTOMATIC DISEASES; CARRIER STATE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HUMANS; OLIGOPEPTIDES; PROLINE; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84870340988     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.10.011     Document Type: Note

References (26)

1. Alter H., Liang T. Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann. Intern. Med. 2012, 156:317-318.
2. Arora S., Thornton K., Murata G. Outcomes of treatment for hepatitis C virus infection by primary care providers. N. Engl. J. Med. 2011, 364:2199-2207.
3. Barreiro P., Vispo E., Labarga P., Soriano V. Management and treatment of chronic hepatitis C in HIV patients. Semin. Liver Dis. 2012, 32:138-146.
4. Department of Health and Human Services Recommendations for the identification of hepatitis C virus chronic infection. CDC Fed. Reg. 2012, 77:30293.
5. Ford N., Singh K., Cooke G., Mills E., von Schoen-Angerer T., Kamarulzaman A. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin. Infect. Dis. 2012, 54:1465-1472.
6. Ge D., Fellay J., Thompson A., Simon J., Shianna K., Urban T., Heinzen E., Qiu P., Bertelsen A., Muir A., Sulkowski M., McHutchison J., Goldstein D. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
7. Ghany M., Nelson D., Strader D., Thomas D., Seeff L. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the AASLD. Hepatology 2011, 54:1433-1444. American Association for Study of Liver Diseases.
8. Lange, C., Zeuzem, S., in press. Perspectives and challenges of interferón-free therapy for chronic hepatitis C. J. Hepatol.
9. Lee M., Yang H., Lu S., Jen C., You S., Wang L., Wang C., Chen W., Chen C. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J. Infect. Dis. 2012, 206:469-477. for the R.E.V.E.A.L.-HCV Study Group.
10. Leon A., Cáceres C., Fernández E. A new multidisciplinary home care telemedicine system to monitor stable chronic HIV-infected patients: a randomized study. PLoS ONE 2011, 6:e14515.
11. Ly K., Xing J., Klevens R., Jiles R., Ward J., Holmberg S. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 2012, 156:271-278.
12. Maruyama, S., Koda, M., Oyake, N., Sato, H., Fujii, Y., Horie, Y., Murawaki, Y., in press. Myocardial injury in patients with chronic hepatitis C infection. J. Hepatol.
13. Monaco S., Ferrari S., Gajofatto A., Zanusso G., Mariotto S. HCV-related nervous system disorders. Clin. Dev. Immunol. 2012, 12:236148.
14. Peters L., Grint D., Lundgren J., Rockstroh J., Soriano V., Reiss P., Grzeszczuk A., Sambatakou H., Mocroft A., Kirk O. HCV viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012, 26:1917-1926. for EuroSIDA in EuroCoord.
15. Rallón N., Naggie S., Benito J.M., Medrano J., Restrepo C., Goldstein D., Shianna K., Vispo E., Thompson A., McHutchison J., Soriano V. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010, 24:F23-F29.
16. Rallón N., Pineda J.A., Soriano V., Neukam K., Vispo E., Rivero A., Labarga P., Caruz A., Restrepo C., Camacho A., Barreiro P., Benito J.M. Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b. J. Acquir. Immune Defic. Syndr. 2012, 60:117-123.
17. Rein D., Smith B., Wittenborn J., Lesesne S., Wagner L., Roblin D., Patel N., Ward J., Weinbaum C. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann. Intern. Med. 2012, 156:263-270.
18. Saifu H., Asch S., Goetz M., Smith J., Graber C., Schaberg D., Sun B. Evaluation of HIV and hepatitis C telemedicine clinics. Am. J. Manag. Care 2012, 18:207-212.
19. Sarkar S., Jiang Z., Evon D., Wahed A., Hoofnagle J. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C Study. J. Hepatol. 2012, 57:946-952.
20. Soriano V. A new era for hepatitis C - new diagnostic tools and new weapons. ACS Med. Chem. Lett. 2012, 7:345-346.
21. Soriano V., Sherman K., Rockstroh J., Dieterich D., Back D., Sulkowski M., Peters M. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-coinfected patients. AIDS 2011, 25:2197-2208.
22. Soriano V., Vispo E., Poveda E., Labarga P., Martin-Carbonero L., Fernandez-Montero J.V., Barreiro P. Directly acting antivirals against hepatitis C virus. J. Antimicrob. Chemother. 2011, 66:1673-1686.
23. Soriano V., Poveda E., Vispo E., Labarga P., Rallón N., Barreiro P. Pharmacogenetics of hepatitis C. J. Antimicrob. Chemother. 2012, 67:523-529.
24. Soriano, V., Vispo, E., Barreiro, P., in press. Hepatitis C therapeutics - highlights from EASL 2012. Clin. Infect. Dis.
25. Thompson M., Aberg J., Hoy J., Telenti A., Benson C., Cahn P., Eron J., Günthard H., Hammer S., Reiss P., Richman D., Rizzardini G., Thomas D., Jacobsen D., Volberding P. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012, 308:387-402.
26. Vispo E., Rallon N., Labarga P., Barreiro P., Benito J.M., Soriano V. Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. J. Clin. Virol. 2012, 55:58-61.